Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
- Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found